Inhibitory Receptors in Immune Homeostasis, Disease and Therapy

摘要 要求支持一个题为免疫抑制受体的Keystone研讨会 稳态，疾病和治疗，由林德Meyaard博士，乔纳森Sedgwick，卡拉Rothlin和 亚历克斯·麦卡锡会议将于2024年1月16日至19日在科罗拉多州布雷肯里奇举行。 虽然抑制性免疫受体领域在过去20年中一直在稳步增长，但人们对抑制性免疫受体的兴趣仍然很大。 自从应用针对这些受体的阻断抗体作为癌症治疗药物以来， 免疫疗法抑制性免疫受体作为一般类别的分子包括数百种免疫抑制剂。 受体跨越先天免疫和适应性免疫。人们日益认识到它们在各个领域的重要性， 生物学的广泛方面刺激了早期尝试将它们作为治疗靶点。更深入地了解 这些受体的机制、特性和应用将继续迅速积累， 特别是当这些开始在癌症中靶向的检查点受体之外被用于治疗时。 这次Keystone研讨会汇集了从事不同方面工作的科学家和医生， 他们的生物学在学术界和工业界的一系列学科中。会议计划反映了如何 这一领域深入到生物学和医学的许多领域，并在全球范围内引起人们的兴趣。 水平

ABSTRACT Support is requested for a Keystone Symposia conference entitled Inhibitory Receptors in Immune Homeostasis, Disease and Therapy, organized by Drs. Linde Meyaard, Jonathon Sedgwick, Carla Rothlin and Alex McCarthy. The conference will be held in Breckenridge, Colorado from January 16-19, 2024. While the field of inhibitory immune receptors has been growing steadily over the past 20 years, interest has accelerated tremendously since the application of blocking antibodies for these receptors as cancer immunotherapies. Inhibitory immune receptors as a general class of molecules comprise hundreds of receptors across both innate and adaptive immunity. The increasing understanding of their relevance across broad facets of biology stimulates early attempts to harness them as therapeutic targets. Deeper insights into the mechanisms, characteristics and applications of these receptors will continue to accumulate rapidly, especially as these begin to be leveraged therapeutically outside the checkpoint receptors targeted in cancer. This Keystone Symposia conference brings together scientists and physicians working on different aspects of their biology across a range of disciplines in academia and industry. The conference program reflects just how deeply this area penetrates into many areas of diverse biology and medicine and garners interest at a global level.